ESLA Q3 2024 Earnings — Estrella Immunopharma, Inc. Revenue & Financial Results | Market Cap Arena

ESLAEstrella Immunopharma, Inc.

$53M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$3M

Net Income

-$3M

EPS (Diluted)

$-0.09

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$4M

Total Liabilities

$3M

Stockholders' Equity

$746,286

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$3M	-$2M	-80.5%
Net Income	-$3M	-$2M	-80.5%